An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease

Jun 23, 2023Hepatobiliary surgery and nutrition

Expert agreement on fatty liver linked to metabolism problems and the risk of chronic kidney disease

AI simplified

Circadian Biology on OpenScience ↗PubMed ↗DOI ↗

Abstract

A panel of 50 experts reached a consensus on the relationship between metabolic dysfunction-associated fatty liver disease (MAFLD) and chronic kidney disease (CKD).

Individuals with MAFLD may be at higher risk of developing CKD compared to those without MAFLD.
The consensus highlighted the need for guidance on managing CKD in patients with MAFLD.
The relationship between the severity of MAFLD and the risk of CKD was emphasized.
Understanding the epidemiology and mechanisms linking MAFLD and CKD is crucial for early prevention.

AI simplified

BACKGROUND: With the rising global prevalence of fatty liver disease related to metabolic dysfunction, the association of this common liver condition with chronic kidney disease (CKD) has become increasingly evident. In 2020, the more inclusive term metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed to replace the term non-alcoholic fatty liver disease (NAFLD). The observed association between MAFLD and CKD and our understanding that CKD can be a consequence of underlying metabolic dysfunction support the notion that individuals with MAFLD are at higher risk of having and developing CKD compared with those without MAFLD. However, to date, there is no appropriate guidance on CKD in individuals with MAFLD. Furthermore, there has been little attention paid to the link between MAFLD and CKD in the Nephrology community.

METHODS AND RESULTS: Using a Delphi-based approach, a multidisciplinary panel of 50 international experts from 26 countries reached a consensus on some of the open research questions regarding the link between MAFLD and CKD.

CONCLUSIONS: This Delphi-based consensus statement provided guidance on the epidemiology, mechanisms, management and treatment of MAFLD and CKD, as well as the relationship between the severity of MAFLD and risk of CKD, which establish a framework for the early prevention and management of these two common and interconnected diseases.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief